Show simple item record

dc.contributor.authorCarles Lavila, Misericordia
dc.contributor.authorVilaprinyo Terré, Ester
dc.contributor.authorCots, Francesc
dc.contributor.authorGregori Gomis, Aleix
dc.contributor.authorPla Farnós, Roger
dc.contributor.authorRomán, Rubén
dc.contributor.authorSala i Serra, Maria
dc.contributor.authorMacià, Francesc
dc.contributor.authorCastells, Xavier
dc.contributor.authorRué i Monné, Montserrat
dc.description.abstractBackground: Breast cancer (BC) causes more deaths than any other cancer among women in Catalonia. Early detection has contributed to the observed decline in BC mortality. However, there is debate on the optimal screening strategy. We performed an economic evaluation of 20 screening strategies taking into account the cost over time of screening and subsequent medical costs, including diagnostic confirmation, initial treatment, follow-up and advanced care. Methods: We used a probabilistic model to estimate the effect and costs over time of each scenario. The effect was measured as years of life (YL), quality-adjusted life years (QALY), and lives extended (LE). Costs of screening and treatment were obtained from the Early Detection Program and hospital databases of the IMAS-Hospital del Mar in Barcelona. The incremental cost-effectiveness ratio (ICER) was used to compare the relative costs and outcomes of different scenarios. Results: Strategies that start at ages 40 or 45 and end at 69 predominate when the effect is measured as YL or QALYs. Biennial strategies 50-69, 45-69 or annual 45-69, 40-69 and 40-74 were selected as cost-effective for both effect measures (YL or QALYs). The ICER increases considerably when moving from biennial to annual scenarios. Moving from no screening to biennial 50-69 years represented an ICER of 4,469€ per QALY. Conclusions: A reduced number of screening strategies have been selected for consideration by researchers, decision makers and policy planners. Mathematical models are useful to assess the impact and costs of BC screening in a specific geographical area.ca_ES
dc.description.sponsorshipThis study was funded by grants PI06/1649, PI06/90355 and PS09/01340 from the Health Research Fund (Fondo de Investigación Sanitaria) of the Spanish Ministry of Health and by grant 068/27/06 from the Catalan Agency for Health Technology Assessment (Agència d'Avaluació de Tecnologia i Recerca Mèdiques).
dc.publisherBioMed Centralca_ES
dc.relation.isformatofReproducció del document publicat a
dc.relation.ispartofBMC Cancer, 2011, vol. 11, núm. 192, p. 1-11ca_ES
dc.rightscc-by, (c) Carles et al., 2011ca_ES
dc.subject.otherMama -- Càncer -- Catalunyaca_ES
dc.subject.otherMama -- Càncer -- Diagnòsticca_ES
dc.subject.otherMama -- Càncer -- Mortalitat -- Catalunyaca_ES
dc.titleCost-effectiveness of early detection of breast cancer in Catalonia (Spain)ca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by, (c) Carles et al., 2011
Except where otherwise noted, this item's license is described as cc-by, (c) Carles et al., 2011